CA2795799C - Anti-erbb3 antibodies - Google Patents

Anti-erbb3 antibodies Download PDF

Info

Publication number
CA2795799C
CA2795799C CA2795799A CA2795799A CA2795799C CA 2795799 C CA2795799 C CA 2795799C CA 2795799 A CA2795799 A CA 2795799A CA 2795799 A CA2795799 A CA 2795799A CA 2795799 C CA2795799 C CA 2795799C
Authority
CA
Canada
Prior art keywords
seq
sh24c05
acid sequence
variable region
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2795799A
Other languages
English (en)
French (fr)
Other versions
CA2795799A1 (en
Inventor
Sylvie Vincent
William M. Winston, Jr.
Fang Wang
Solly Weiler
Kristan Meetze
Lyne Breault
Steve Botega
Ting Chen
Michael Deprima
Christina Fleet
Steven Tyler
Jin-Kyeung Woo
Jeno Gyuris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aveo Pharmaceuticals Inc
Original Assignee
Aveo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc filed Critical Aveo Pharmaceuticals Inc
Publication of CA2795799A1 publication Critical patent/CA2795799A1/en
Application granted granted Critical
Publication of CA2795799C publication Critical patent/CA2795799C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2795799A 2010-04-09 2011-04-08 Anti-erbb3 antibodies Active CA2795799C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32271210P 2010-04-09 2010-04-09
US61/322,712 2010-04-09
PCT/US2011/031829 WO2011136911A2 (en) 2010-04-09 2011-04-08 Anti-erbb3 antibodies

Publications (2)

Publication Number Publication Date
CA2795799A1 CA2795799A1 (en) 2011-11-03
CA2795799C true CA2795799C (en) 2018-09-25

Family

ID=44120965

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2795799A Active CA2795799C (en) 2010-04-09 2011-04-08 Anti-erbb3 antibodies

Country Status (18)

Country Link
US (6) US8481687B2 (enExample)
EP (1) EP2566895B1 (enExample)
JP (1) JP5906233B2 (enExample)
KR (1) KR101764453B1 (enExample)
CN (2) CN102884085B (enExample)
AR (1) AR080873A1 (enExample)
AU (1) AU2011245636B2 (enExample)
BR (1) BR112012025730B1 (enExample)
CA (1) CA2795799C (enExample)
ES (1) ES2566602T3 (enExample)
IL (1) IL222272B (enExample)
MX (1) MX343227B (enExample)
NZ (1) NZ603271A (enExample)
PH (1) PH12012502022B1 (enExample)
RU (1) RU2568051C2 (enExample)
SG (1) SG184452A1 (enExample)
WO (1) WO2011136911A2 (enExample)
ZA (1) ZA201208290B (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5173838B2 (ja) 2006-02-13 2013-04-03 アレシア・バイオセラピューティクス・インコーポレーテッド 骨リモデリングのプロセスと関係があるポリヌクレオチドおよびポリペプチド配列
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
AU2008230795B2 (en) 2007-03-27 2014-05-29 Bioassets, Llc Constructs and libraries comprising antibody surrogate light chain sequences
US20120128671A1 (en) 2009-05-13 2012-05-24 Lawrence Horowitz Neutralizing molecules to influenza viruses
PH12012501157A1 (en) 2009-12-22 2012-10-29 Roche Glycart Ag Anti-her3 antibodies and uses thereof
KR101764453B1 (ko) 2010-04-09 2017-08-02 아베오 파마슈티컬즈, 인크. 항-erbb3 항체
ME02637B (me) 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
WO2012059857A2 (en) 2010-11-01 2012-05-10 Symphogen A/S Pan-her antibody composition
ITRM20100577A1 (it) 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
US20140134170A1 (en) 2011-03-11 2014-05-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
EP2815765A1 (en) 2011-03-15 2014-12-24 Merrimack Pharmaceuticals, Inc. Overcoming resistance to ERBB pathway inhibitors
MX336197B (es) 2011-04-19 2016-01-11 Merrimack Pharmaceuticals Inc Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos.
CA2842860A1 (en) * 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Sur-binding proteins
WO2013033008A2 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
WO2013048883A2 (en) 2011-09-30 2013-04-04 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
EP2764364B1 (en) * 2011-10-06 2021-08-18 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-erbb3 antibodies
CN108424456B (zh) 2011-11-23 2022-04-26 医学免疫有限责任公司 特异于her3的结合分子及其用途
EP2788382A2 (en) * 2011-12-05 2014-10-15 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
CN108341873B (zh) * 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
EP2788381A2 (en) * 2011-12-05 2014-10-15 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
AU2013293062A1 (en) 2012-07-19 2014-07-24 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
SG11201506451UA (en) 2013-03-06 2015-09-29 Merrimack Pharmaceuticals Inc Anti-c-met tandem fc bispecific antibodies
EP2821071A1 (en) 2013-07-04 2015-01-07 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compounds for breast cancer treatment
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10538591B2 (en) * 2014-03-10 2020-01-21 The Brigham And Women's Hospital, Inc. Anti-fibulin-3 antibodies and uses thereof
TW201622743A (zh) * 2014-03-19 2016-07-01 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 免疫原醣肽、包含該醣肽之組合物及其用途
ES2772817T3 (es) 2014-04-10 2020-07-08 Obi Pharma Inc Anticuerpos de unión a antígenos de carbohidrato asociados a tumor, composiciones farmacéuticas y sus usos
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
US10526416B2 (en) 2014-09-08 2020-01-07 Yeda Research And Development Co. Ltd. Anti-HER3 antibodies and uses of same
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
KR102390359B1 (ko) * 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
CN104861068B (zh) * 2015-01-23 2020-11-17 中国人民解放军军事科学院军事医学研究院 一种全人源抗her3抗体及其治疗相关疾病的用途
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
AU2016335842A1 (en) * 2015-10-07 2018-04-12 Obi Pharma, Inc. Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
US20180346571A1 (en) * 2015-11-17 2018-12-06 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
WO2017091615A1 (en) * 2015-11-24 2017-06-01 Cellerant Therapeutics, Inc. Humanized anti-cll-1 antibodies
KR101746152B1 (ko) * 2015-12-07 2017-06-13 주식회사 이수앱지스 ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
WO2017160990A1 (en) 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
US11155617B2 (en) * 2016-06-23 2021-10-26 Jiangsu Hengrui Medicine Co., Ltd. LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
CN106692969B (zh) * 2016-12-08 2021-08-10 北海康成（北京）医药科技有限公司 抗erbb3抗体及其用途
US11787858B2 (en) 2016-12-22 2023-10-17 Icahn School Of Medicine At Mount Sinai Anti-LILRB3 antibodies and methods of use thereof
US12667557B2 (en) 2017-02-28 2026-06-30 Daiichi Sankyo Company, Limited Method for treating EGFR-TKI-resistant non-small cell lung cancer by administration of anti-HER3 antibody-drug conjugate
TWI771389B (zh) 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
MX2019011252A (es) * 2017-03-23 2020-01-23 Univ Pennsylvania Anticuerpos anti-c5a y usos de los mismos.
CN113684275B (zh) * 2017-06-22 2024-02-27 北海康成（北京）医药科技有限公司 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
JP7280238B2 (ja) * 2017-07-17 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法
JP7795860B2 (ja) 2017-09-07 2026-01-08 オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド プログラム細胞死タンパク質１に対する抗体
CN111094339B (zh) * 2017-10-17 2023-01-24 江苏恒瑞医药股份有限公司 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
TW201946654A (zh) 2018-03-05 2019-12-16 比利時商健生藥品公司 抗ＰＨＦ－Ｔａｕ抗體及其用途
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
MX2020010094A (es) 2018-04-06 2021-01-15 Dana Farber Cancer Inst Inc Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
WO2020059772A1 (ja) 2018-09-20 2020-03-26 第一三共株式会社 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
US20220106398A1 (en) * 2019-02-08 2022-04-07 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
CN113811329B (zh) * 2019-04-19 2025-10-14 天科雅生物科技有限公司 抗pd-1抗体和其用途
CN118465272B (zh) * 2019-12-04 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
WO2021167952A2 (en) * 2020-02-20 2021-08-26 The Feinstein Institutes For Medical Research Agonist antibodies against endoglin and uses thereof
US20240067738A1 (en) * 2020-03-18 2024-02-29 Elanco Us Inc. Anti-il4 receptor antibodies for veterinary use
TW202227486A (zh) * 2021-01-04 2022-07-16 大陸商上海翰森生物醫藥科技有限公司 一種抗erbb3受體的抗體或其抗原結合片段及其醫藥用途
WO2023147470A2 (en) 2022-01-28 2023-08-03 Georgiamune Inc. Antibodies to programmed cell death protein 1 that are pd-1 agonists
CN114940714B (zh) * 2022-05-20 2023-06-16 湖南师范大学 肝癌标志物soat1单克隆抗体制备及其应用
EP4536278A4 (en) 2022-06-07 2026-08-12 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
CN115109161B (zh) * 2022-06-28 2023-08-11 广东赛尔生物科技有限公司 含有间充质干细胞的减肥药物组合物
CN115806619B (zh) * 2022-10-09 2026-08-04 苏州市立医院 一种单克隆抗体及其用途
EP4637821A1 (en) * 2022-12-23 2025-10-29 Actinium Pharmaceuticals, Inc. Her3 radioimmunotherapy for the treatment of solid cancers
JPWO2024248123A1 (enExample) 2023-06-02 2024-12-05
AU2024415931A1 (en) 2023-12-27 2026-07-16 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Multi-specific antibody targeting her3 and trop2 and conjugate thereof
CN118005795B (zh) * 2024-04-09 2024-06-28 天津旷博同生生物技术有限公司 一种抗人cd64抗体及应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
DK0896586T4 (en) * 1996-03-27 2015-08-24 Genentech Inc ErbB3 antibodies.
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
US20070009972A1 (en) 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
NZ579644A (en) * 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
JP2012525432A (ja) 2009-04-29 2012-10-22 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー ヘレグリン共役型ｈｅｒ３と免疫反応性の改善された抗体
AU2010284018C1 (en) 2009-08-21 2015-10-15 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of ErbB3 and uses thereof
CA2775573A1 (en) 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
PH12012501157A1 (en) 2009-12-22 2012-10-29 Roche Glycart Ag Anti-her3 antibodies and uses thereof
KR101764453B1 (ko) 2010-04-09 2017-08-02 아베오 파마슈티컬즈, 인크. 항-erbb3 항체
CA2813796C (en) * 2010-10-18 2019-01-15 Mediapharma S.R.L. Erbb3 binding antibody
EP2764364B1 (en) * 2011-10-06 2021-08-18 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-erbb3 antibodies

Also Published As

Publication number Publication date
US11680108B2 (en) 2023-06-20
AR080873A1 (es) 2012-05-16
IL222272A0 (en) 2012-12-31
BR112012025730A8 (pt) 2017-05-23
BR112012025730B1 (pt) 2020-12-08
US20110256154A1 (en) 2011-10-20
WO2011136911A3 (en) 2012-03-08
PH12012502022B1 (en) 2019-03-08
US10494441B2 (en) 2019-12-03
US12486332B2 (en) 2025-12-02
EP2566895B1 (en) 2015-12-30
MX2012011718A (es) 2012-12-17
AU2011245636A2 (en) 2012-11-29
EP2566895A2 (en) 2013-03-13
US20180030149A1 (en) 2018-02-01
RU2568051C2 (ru) 2015-11-10
US20160264679A1 (en) 2016-09-15
SG184452A1 (en) 2012-11-29
RU2012147591A (ru) 2014-05-20
US20130330772A1 (en) 2013-12-12
CN102884085A (zh) 2013-01-16
CN102884085B (zh) 2016-08-03
NZ603271A (en) 2014-05-30
PH12012502022A1 (en) 2013-01-21
ZA201208290B (en) 2013-07-31
US9598498B2 (en) 2017-03-21
AU2011245636B2 (en) 2016-12-22
KR20130043106A (ko) 2013-04-29
US20230365710A1 (en) 2023-11-16
CN105968206A (zh) 2016-09-28
HK1178184A1 (zh) 2013-09-06
KR101764453B1 (ko) 2017-08-02
US9228021B2 (en) 2016-01-05
US20200299406A1 (en) 2020-09-24
IL222272B (en) 2018-04-30
US8481687B2 (en) 2013-07-09
ES2566602T3 (es) 2016-04-14
MX343227B (es) 2016-10-28
JP5906233B2 (ja) 2016-04-20
WO2011136911A2 (en) 2011-11-03
CN105968206B (zh) 2020-01-17
CA2795799A1 (en) 2011-11-03
BR112012025730A2 (pt) 2017-01-10
JP2013523166A (ja) 2013-06-17

Similar Documents

Publication Publication Date Title
US12486332B2 (en) Anti-ERBB3 antibodies
AU2011245636A1 (en) Anti-ErbB3 antibodies
US12258391B2 (en) Anti-GDF-15 antibodies
US8829164B2 (en) Anti-ron antibodies
WO2011156617A2 (en) Anti-egfr antibodies
CN106692969B (zh) 抗erbb3抗体及其用途
KR20240007760A (ko) 항-icos 항체의 용도

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160404

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250404

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250404